Replies to post #53020 on Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

I also think there is a lot we don't know about the delay in the Amgen trial and amendment to the IND and that what is happening on that front will tie back directly to any potential M&A transaction going into the March 2018 annual meeting, retention bonuses of key remaining employees until March and ridding of the road block to shareholder value creation (O'Connor).

[abuhafsa]

I sincerely hope you are right so we can all dig ourselves out of the hole we find ourselves in. But I've seen such 'reading of the tea leaves' and putting '2+2 together' efforts prove to be completely off the mark in the past, so I remain skeptical.

[cab033]

That is exactly what I think it is, just a coincidence. IMO I think the EMA application is filed with little to no reaction from the market. I think the March retention date will come and go with no activity. And finally I think the March Meeting will get here and the authorized shares will be approved. That is what I think near term. Further out I think Bonstein following DOC and Lombardo issuing shares in the $5 range right around ASCO. The issuance will probably put pressure on the SP as it usually does pushing this back to the 4’s.

Just my thoughts, and the only reason I think this is because based on historical events, this has the highest likely hood of how it will actually play out. Not being optimistic or negative, just reading it how it is, without reading between the lines. If this is how it ends up playing out, looking back it will be obvious that it happened that way.